Top 10 Us Pharmaceutical Companies - The global market for prescription pharmaceuticals was estimated at $1,114 billion in 2015. The market is mature and very consolidated. In 2015, the share of the top-10 pharmaceutical companies in this market was more than 30%. These companies are large and established entities primarily based in the United States and Europe. They offer pharmaceutical products for a wide range of therapeutic areas. In addition, these organizations have the potential for research and development in life sciences. The combined R&D expenditure of these ten companies exceeds the R&D budget for life science research in the public sector.
A comparative analysis of top-10 organizations was done to prepare the ranking for these companies. The classification model included six criteria for each organization: revenue, contribution of top 3 pharmaceutical products to revenue, annual growth, investment in R&D, expenditure and income, and income per employee. A scoring statistic was developed based on these six criteria. Each organization was awarded a score for each of these six criteria. A weighted sum of the six criteria was used to arrive at the final score figure. Total income received the highest weighting (40%), while per employee income received the lowest weighting (6%). The scoring figures represent the financial position, R&D strength and diversity of each organization's product portfolio.
Top 10 Us Pharmaceutical Companies
Johnson & Johnson (US) is the highest ranked organization in this list. The company had the highest revenue in 2015. Its pharmaceutical division contributed 44.85% of its revenue in 2015. The company had the largest R&D budget in 2015. However, the most important reason for its high rank is its product variety. , Portfolio – The contribution of its top-3 drugs to pharmaceutical revenue (35.84%) was the lowest in this list. Remicade, Stelara and Zytiga were the top-3 drugs for the company in 2015. The combined revenue of these three products was US$11,266 million in 2015.
How Pharmaceutical Companies Use Facebook To Engage Customers
Hoffmann-La Roche AG had revenues of US$50,111 million in 2015. Its pharmaceutical segment contributed 77.54% of its revenue in 2015. The company had the highest R&D expenditure in 2015 – USD 9,972 million. However, the company's product portfolio is narrow. Avastin, Herceptin and Rituxan were the top-3 drugs for Roche in 2015. In 2015, their contribution to the company's revenue was 50.53%. All these three products are related to oncology. Furthermore, the patents for these three products are due to expire in a few years (2016 for Avastin and Herceptin and 2019 for Rituxan). This exposes the company to competition from biosimilars.
Pfizer Inc. It had revenue of US$48,851 million in 2015. The R&D expenditure of companies in 2015 was US$7,690 million. The company's top-3 pharmaceutical products contributed 27.09% to the company's revenue in 2015. Pfizer has one of the lowest ratios of revenue to total revenue from its top-3 drugs, indicating a portfolio of healthy products. In addition, its best-selling drug, Prevnar, has a patent expiration horizon of 2026, which will help the company maintain its market position.
Novartis AG's total revenue in 2015 was US$49,414 million. The revenue of the company decreased by 5.30% as compared to the previous year. The company invested USD 8,935 million in R&D in 2015. The company also has a diversified product offering, with the top-3 pharmaceutical products contributing only 31.18% of the company's pharmaceutical revenue in 2015. The company's top-3 drugs in 2015 were Glivec, Gilenya and Lucentis. The combined sales of these 3 products in 2015 were USD 9,494 million.
Bayer AG is the only German company on this list. Although its total revenue was higher than that of Roche, Pfizer and Novartis, its pharmaceutical segment revenue was lower – US$15,253 million in 2015. The reported ratio of revenue from its top-3 drugs to total revenue was one of the lowest for Pfizer – 33.72% in 2015.
Top 15 Pharma Companies In India
Merck & Co., Inc. It had a total revenue of USD 39,498 million in 2015. The company's pharmaceutical division contributed 88.06% of this figure in 2015. The company invested US$6,704 million in R&D in 2015, one of the highest in relation to their income. Furthermore, the contribution of the top-3 drugs to revenue was one of the lowest (24.55% in 2015) for Merck, second only to GSK in the report.
GlaxoSmithKline plc is the first UK company to feature in the list. Its total revenue in 2015 was US$36,566 million. The company invested US$5,441 million in R&D in 2015. The proportion of contribution of top-3 drugs to the company's revenue was the lowest - 21.50% in 2015.
Sanofi is the only French company on this list. It was one of two companies on this list with a positive growth rate in 2015. The company's revenue grew by 8.99% between 2014 and 2015, reaching US$34,542 million in 2015. The company invested US$5,092 million in R&D in 2015. Only 29.06% of its revenue in 2015. However, patents on all three products have expired since 2014, and the company needs to rapidly expand and diversify its product offering.
Gilead Sciences, Inc. The highest growth rate was in 2015. The company grew by 31.13% between 2014 and 2015, reaching USD 32,639 million in 2015. The company invested US$3,014 million in R&D in 2015. 3 drugs – Harvoni, Sovaldi and Truvada – contributed 55.48% of its revenue in 2015. This ratio is also the highest among its peers on this list. However, the patent expiration horizons for all three products are very long (2030 for Harvoni, 2029 for Sovaldi and 2021 for Truvada), which helped support the company's rapid growth.
Top 10 Pharmaceutical Companies 2016
AstraZeneca plc had revenues of US$23,641 million in 2015. The company invested US$5,997 million in R&D in 2015. The company had the highest R&D investment in relation to its revenue of all the companies on this list. The company's strategy to invest in R&D is critical to its growth, as its top-3 drugs -- which contributed 46.14% of its revenue in 2015 -- are fast approaching patent expiration. Crestor and Nexium's patents expire in 2016, while Symbicort expires in 2017. Our 20th annual list highlights brand growth, new assortment battles and increased M&A, but capped by COVID-19, a look behind the numbers tells another story.
Brand growth, new ranking battles, and M&A growth highlight Pharm Exec's annual list of the top global biopharma players, but in the shadow of COVID-19, even a look behind the numbers tells another story -- a Which reinforces the broader health of the industry. Mission
Much of the world's attention today is naturally focused on the global COVID-19 crisis - and for governments, the health and medical communities, and others, focused directly on the critical response, resources, and discovery efforts to end the pandemic It may seem like an odd comparison to highlight our annual list of the top 50 best-selling biopharma manufacturers.
Or could it be that this background actually offers a very real context or perspective for this year's book, our 20th? Perhaps never more clearly than today is the purpose and strength that has long been needed to fight not only cancer or crippling chronic conditions, but unpredictable viral crises like COVID-19; Ebola, Swine Flu and HIV/AIDS first; And the next pandemic to come.
Visualizing The World's Biggest Pharmaceutical Companies
After all, many of the companies that made our list are on the front lines in the fight against the current crisis through treatment, outreach, education, and research (see here) — and will likely be for the next one. Some have launched their own initiatives, many are working together (for example, the COVID-19 Therapeutics Accelerator Consortium, made up of 12 organizations in our Pharma 50), and others are partnering with government (For example, Operation Warp Speed, United States Department of State). Health and Human Services agreement with AstraZeneca to accelerate the development and manufacturing of a coronavirus vaccine developed by the University of Oxford).
And as annual prescription drug revenue and R&D spending totals show, it is the ability of these companies, collectively, to generate output and sustain investment that ultimately helps transform new science and lead to approved products or significant breakthroughs. Innovation in treatment modifications holds promise. Pfizer's announcement earlier this month to commit $500 million to a range of biotechs in clinical stage -- and allowing access to Pfizer resources in research, clinical development and manufacturing -- is one such example.
As for the most recent pharmaceutical revenue accounts for the full year, our latest Pharma 50 rankings have had little financial impact of COVID. However, the top 10 positions experienced their biggest shock in many years, affected in part by a couple of mega events. Fusion. Roche moved up one spot to end Pfizer's four-year reign at the top of the rankings, with an 8.3% increase in Rx sales. Avastin, which represents 15% of the company's total pharmaceutical revenue, remains Roche's top seller, but like Herceptin and Rituxan, it faces biosimilar competition in the coming years. As reinforcements emerge, key sales drivers for Roche include multiple sclerosis drug Ocrevus, hemophilia drug Hemlibra, and cancer treatments Tescentric and Parjeta. in
Top 10 oncology pharmaceutical companies, top 10 pharmaceutical companies 2020, top 10 uk pharmaceutical companies, top us pharmaceutical companies, top 10 generic pharmaceutical companies, top 10 global pharmaceutical companies, top 10 pharmaceutical companies worldwide, top 10 pharmaceutical companies, top 10 largest pharmaceutical companies, top 10 pharmaceutical companies india, top 10 biggest pharmaceutical companies, top 10 world pharmaceutical companies
